Skip Navigation LinksHome > January 2014 - Volume 21 - Issue 1 > Inhibitors of CXC chemokine receptor type 4: putative therap...
Current Opinion in Hematology:
doi: 10.1097/MOH.0000000000000002
MYELOID BIOLOGY: Edited by David C. Dale

Inhibitors of CXC chemokine receptor type 4: putative therapeutic approaches in inflammatory diseases

Hummel, Stephaniea,b; Van Aken, Hugoa; Zarbock, Alexandera,b

Collapse Box

Abstract

Purpose of review

The CXC chemokine receptor type 4 (CXCR4), which is a G-protein coupled receptor, and its ligand CXCL12 play an important role in neutrophil homeostasis and inflammation. This review focuses on involvement of the CXCL12/CXCR4 axis in inflammation and different inflammatory diseases and depicts that blocking CXCR4 is an attractive therapeutic strategy.

Recent findings

Binding of CXCL12 to CXCR4 retains immature neutrophils in the bone marrow and also participates in leukocyte recruitment into inflamed tissue. The CXCL12/CXCR4 axis is also involved in several inflammatory processes and diseases including the WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome, HIV, autoimmune disorders, ischemic injury, and pulmonary fibrosis.

Summary

Based on these findings, blocking CXCR4 seems to be a therapeutic strategy in inflammatory diseases. Several promising CXCR4 antagonists are in different stages of development and clinical trials. Currently, only plerixafor (AMD3100) has been approved for short-term application.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.